Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients.

The objective of this study was to evaluate the Bayesian predictability of vancomycin (VCM) pharmacokinetics in Japanese pediatric patients using one-compartment population pharmacokinetic (PPK) parameters, which we reported previously. The validity of the PPK model was evaluated by bootstrap method and cross validation method, and the Bayesian predictive performance was examined. The predictive performance of the PPK model for premature patients was also examined. The cross validation method showed the predictability to be acceptable for practical use, especially for predicting trough concentration using other trough data. However, for the external premature patient data, this PPK model did not seem to be adequate. A theoretical approach using a simulation technique was also examined to evaluate the predictive performance. The results suggested that the predictability at the peak was not necessarily good at all sampling times and the predictability at the trough was better when a later time point was used. The optimal sampling time for prediction of VCM concentration in pediatric patients is discussed.

[1]  J. N. van den Anker,et al.  Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.

[2]  Toru Ishibashi,et al.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. , 2003, British journal of clinical pharmacology.

[3]  K. Shimada.  [Recent findings based on the results of the post-marketing surveillance of vancomycin hydrochloride for intravenous infusion]. , 2003, The Japanese journal of antibiotics.

[4]  A. Ohnishi,et al.  Evaluation of Bayesian predictability of vancomycin concentration in patients with various degrees of renal function. , 2001, Biological & pharmaceutical bulletin.

[5]  M. Barclay,et al.  The therapeutic monitoring of antimicrobial agents. , 2001, British journal of clinical pharmacology.

[6]  R. Wrishko,et al.  Vancomycin Pharmacokinetics and Bayesian Estimation in Pediatric Patients , 2000, Therapeutic drug monitoring.

[7]  T. Iga,et al.  Population pharmacokinetics of vancomycin in Japanese pediatric patients. , 1998, Therapeutic drug monitoring.

[8]  K. Rodvold,et al.  Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children , 1997, Clinical pharmacokinetics.

[9]  E. Ette,et al.  Stability and Performance of a Population Pharmacokinetic Model , 1997, Journal of clinical pharmacology.

[10]  K. Masunaga,et al.  Pharmacokinetic Studies of Vancomycin Hydrochloride (VCM) in Premature Infants , 1996 .

[11]  M. Levine,et al.  Vancomycin Pharmacokinetics and Dosing in Premature Neonates , 1995, Therapeutic drug monitoring.

[12]  K. Rodvold,et al.  Bayesian Forecasting of Serum Vancomycin Concentrations in Neonates and Infants , 1995, Therapeutic drug monitoring.

[13]  W. Leader,et al.  Pharmacokinetic Optimisation of Vancomycin Therapy , 1995, Clinical pharmacokinetics.

[14]  Koichi Nishimura,et al.  Predictive performance of the Bayesian analysis: Effects of blood sampling time, population parameters, and pharmacostatistical model , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[15]  Jarrett Rv,et al.  Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants , 1993 .

[16]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  R W Jelliffe,et al.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens , 1990, Antimicrobial Agents and Chemotherapy.

[18]  M. Rybak,et al.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside. , 1990, The Journal of antimicrobial chemotherapy.

[19]  J. Rotschafer,et al.  Evaluation of a Two‐Compartment Bayesian Forecasting Program for Predicting Vancomycin Concentrations , 1989, Therapeutic drug monitoring.

[20]  R. Slaughter,et al.  Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. , 1987, The American journal of medicine.

[21]  G. Matzke,et al.  Clinical Pharmacokinetics of Vancomycin , 1986, Clinical pharmacokinetics.

[22]  D. D’Argenio,et al.  Adaptive control of theophylline therapy: Importance of blood sampling times , 1983, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  T. Sorrell,et al.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus. , 1982, Annals of internal medicine.

[24]  A W Kelman,et al.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. , 1982, British journal of clinical pharmacology.

[25]  G. Mccracken,et al.  Pharmacology and Efficacy of Vancomycin for Staphylococcal Infections in Children , 1981 .

[26]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  T. Iga,et al.  Population pharmacokinetics of vancomycin in Japanese adult patients. , 1998, Therapeutic drug monitoring.

[28]  S. Duffull,et al.  Vancomycin toxicity. What is the evidence for dose dependency? , 1994, Adverse drug reactions and toxicological reviews.

[29]  J. W. Bass,et al.  Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. , 1993, The Pediatric infectious disease journal.

[30]  R. Moellering.  Pharmacokinetics of vancomycin. , 1984, The Journal of antimicrobial chemotherapy.

[31]  G. Mccracken,et al.  Pharmacology and efficacy of vancomycin for staphylococcal infections in children. , 1981, Reviews of infectious diseases.

[32]  G. Mccracken,et al.  Clinical pharmacology and efficacy of vancomycin in pediatric patients. , 1980, The Journal of pediatrics.